While multiple reports have described the constitutively active oncogenic KRAS to be independent of EGFR [12–13], recent evidence in pancreatic cancer has indicated that signaling by mutant KRAS may be dependent on upstream activation proposed of EGFR [14–15]. This evidence concerns the gene KRAS and pancreatic neoplasm.